Statin use and risk for type 2 diabetes: what clinicians should know

References

• Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012;380:565–571.
   PubMed Web of Science ®Google Scholar
• Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet. 2010;375:735–742.
   PubMed Web of Science ®Google Scholar
• Preiss D, Seshasai SRK, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305:2556–2564.
   PubMed Web of Science ®Google Scholar
• Waters DD, Ho JE, Boekholdt SM, et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol. 2013;61:148–152.
   PubMed Web of Science ®Google Scholar
• Casula M, Mozzanica F, Scotti L, et al. Statin use and risk of new-onset diabetes: a meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2017;27:396–406.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376:1670–1681.
   PubMed Web of Science ®Google Scholar
• Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375:2144–2153.
   PubMed Web of Science ®Google Scholar
• Cohen JC. Emerging LDL therapies: using human genetics to discover new therapeutic targets for plasma lipids. J Clin Lipidol. 2013;7:S1–5.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58:773–795.
   PubMed Web of Science ®Google Scholar
• Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med. 2012;172:144–152.
   PubMed Web of Science ®Google Scholar
• Cederberg H, Stancakova A, Yaluri N, et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. Diabetologia. 2015;58:1109–1117.
   PubMed Web of Science ®Google Scholar
• Mansi I, Frei CR, Wang C-P, et al. Statins and new-onset diabetes mellitus and diabetic complications: a retrospective cohort study of US healthy adults. J Gen Intern Med. 2015;11:1599–1610.
   Web of Science ®Google Scholar
• Corrao G, Ibrahim B, Nicotra F, et al. Statins and the risk of diabetes: evidence from a large population-based cohort study. Diabetes Care. 2014;37:2225–2232.
   PubMed Web of Science ®Google Scholar
• Crandall JP, Mather K, Rajpathak SN, et al. Statin use and risk of developing diabetes: results from the Diabetes Prevention Program. BMJ Open Diab Res Care. 2017:e000438.
   PubMed Web of Science ®Google Scholar
• Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet. 2015;385:351–361.
   PubMed Web of Science ®Google Scholar
• Maki KC, Ridker PM, Brown V, et al. An assessment by the statin diabetes safety task force: 2014 update. J Clin Lipidol. 2014;8:S17–S29.
   PubMed Web of Science ®Google Scholar
• Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet. 2016;388:2532–2561.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration, Baigent C, Keech A, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.
   PubMed Web of Science ®Google Scholar
• Cholesterol Treatment Trialists’ (CTT) Collaboration, Mihaylova B, Emberson J, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380:581–590.
   PubMed Web of Science ®Google Scholar
• Bang H, Edwards AM, Bomback AS, et al. A patient self-assessment diabetes screening score: development, validation, and comparison to other diabetes risk assessment scores. Ann Intern Med. 2009;151:775–783.
   PubMed Web of Science ®Google Scholar
• Maki KC, Abraira C, Cooper RS. Arguments in favor of screening for diabetes in cardiac rehabilitation. J Cardiopulmonary Rehab. 1995;15:97–102.
   PubMedGoogle Scholar
• Aroda VR, Knowler WC, Crandall JP, et al. Metformin for diabetes prevention: insights gained from the Diabetes Prevention Program/Diabetes Prevention Program Outcomes Study. Diabetologia. 2017;60:1601–1611.
   PubMed Web of Science ®Google Scholar
• Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2016 executive summary. Endocr Pract. 2016;22(1):84–113.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2017. Diabetes Care. 2017;40(Suppl 1):S1–S142.
   PubMedGoogle Scholar
• 2015–2020 Dietary Guidelines for Americans. 8th ed. [internet]. U.S. Department of Health and Human Services and U.S. Department of Agriculture; 2015. Available from http://health.gov/dietaryguidelines/2015/guidelines/
   Google Scholar
• Tseng E, Yeh HC, Maruthur NM, et al. Metformin use in prediabetes among U.S. adults, 2005-2012. Diabetes Care. 2017;40(7):887–893.
   PubMed Web of Science ®Google Scholar
• Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–2397.
   PubMed Web of Science ®Google Scholar
• Blazing M. European Society of Cardiology Congress. London (UK): 2015 Sep 1. Available from: http://www.acc.org/latest-in-cardiology/articles/2015/11/20/14/20/incidence-of-new-onset-diabetes-in-the-improve-it-trial
   Google Scholar
• US Food and Drug Administration [internet]. 2011. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022362s007lbl.pdf
   Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolucumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–1722.
   PubMed Web of Science ®Google Scholar
• HPS3/TIMI55-REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med. 2017;377:1217–1227.
   Web of Science ®Google Scholar
• US Food and Drug Administration [internet]. 2015. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125522s000lbl.pdf
   Google Scholar
• US Food and Drug Administration [internet]. 2012. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022363s008s009lbl.pdf
   Google Scholar
• Vallejo-Vaz AJ, Seshasai SRK, Kurogi K, et al. Effect of pitavastatin on glucose, HbA1c and incident diabetes: a meta-analysis of randomized controlled clinical trials in individuals without diabetes. Atherosclerosis. 2015;241:409–418.
   PubMed Web of Science ®Google Scholar
• Davis S. Diabetogenic drugs: treating chronic conditions to minimize new onset diabetes: review. SA Pharmaceutical J. 2010;77(10):22–33.
   Google Scholar